-
Mircera Global Market Report: Key Growth Drivers, Trends, and Opportunities from 2025 to 2034
21 Jan 2025 05:51 GMT
… treatment options to manage anemia more effectively, adoption of Mircera in various medical … -centric drug delivery systems.
Get Your Free Sample of The Mircera Market … Major Companies in the Mircera Market?
Notably, pharmaceutical giant Roche is one …
-
Subcutaneous Biologics Market, Industry Trends And Global Forecasts To 2035: Subcutaneous Biologics Set To Transform Drug Delivery And Patient Adherence
16 Jan 2025 13:02 GMT
… offering targeted treatments with minimal drug interactions. Historically … (Amgen) STELARA (Janssen Biotech) Trulicity (Eli Lilly) … Pacific Alteogen Foresee Pharmaceuticals SUBCUTANEOUS FORMULATION TECHNOLOGIES: … KINERET LANTUS LEQVIO Mircera MOUNJARO NPLATE …
-
Aviceda raises $207.5m for eye drug, and other financings
08 Jan 2025 14:20 GMT
… care, given current treatments offer limited benefits … last few days, Danish biotech Orbis Medicines completed a €90 million … 39;s Alebund Pharmaceutical – which specialises in drugs for kidney diseases … red blood cell stimulator Mircera (PEG-epoetin beta) …
-
Chugai Pharmaceutical : Q1 Results (Jan-Mar 2024)
24 Apr 2024 08:09 GMT
… , a subcutaneous combination drug containing Perjeta.
Specialty … In addition, sales of Mircera (a long-acting erythropoiesis … China by the National Medical Products Administration (NMPA) … the treatment of endometriosis in January 2024.
Chugai Pharmaceutical Co …
-
Erythropoietin Drugs Market valued at US$13.803 billion in 2022, to witness significant growth
20 Feb 2024 14:23 GMT
… developed through biotechnological processes and … pharmaceutical products and medical treatments.
The market analytics report segments the erythropoietin drugs … Pharmaceuticals Ltd.
• FosunPharma
• Rewine Pharmaceuticals
• Kyowa Kirin
• Mircera
…
-
Genexine seeks approval for anemia treatment in Korea
26 Jan 2024 10:38 GMT
Korean biotech firm Genexine announced Friday … Efesa is intended for the treatment and maintenance of anemia induced … Genexine started phase 3 clinical trials for patients with non-dialysis … 39;s third-generation anemia drug Mircera maintained a response rate of …
-
Genexine completes BLA submission for anemia treatment
26 Jan 2024 07:24 GMT
… Drug Safety (MFDS) for Efesa (efepoetin alfa), its anemia treatment … Drug Authority (BPOM) after the successful completion of phase 3 clinical trials … Mircera.
“Based on the phase 3 clinical trial results … domestic biotech company to complete the entire drug …
-
Chugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 12-Month High at $19.68
12 Jan 2024 15:19 GMT
… sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …
-
Chugai Pharmaceutical (OTCMKTS:CHGCY) Reaches New 1-Year High at $19.61
29 Dec 2023 17:03 GMT
… sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …
-
Short Interest in Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) Declines By 81.1%
14 Dec 2023 18:42 GMT
… sale, importation, and exportation of pharmaceuticals in Japan and internationally. The … Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an … analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat …
About
© 1995-2025